26.09.2011,
in
Soci 2011
HELSINN GROUP
HELSINN GROUP AND EISAI INC. ANNOUNCE START OF PHASE III CLINICAL PROGRAM OF ORAL FIXED-DOSE COMBINATION OF NETUPITANT/ PALONOSETRON (300 mg/0.50 mg) FOR PREVENTION OF CHEMOTHERAPYINDUCED NAUSEA AND VOMITING (CINV)
20.09.2011,
in
Soci 2011
Helsinn Therapeutics Initiates Global Pivotal Phase III Clinical Program to Evaluate Anamorelin in Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia
13.09.2011,
in
Assemblea 2011
Assemblea generale ordinaria 2011
Presentazione mostra fotografica: "Industria e Architettura, la sorpresa della farmaceutica ticinese"
06.09.2011,
in
Soci 2011
Cerbios confirmed by D&B in the top 500 Swiss companies with Risk Indicator 1
In June 2011, Cerbios received from Dun & Bradstreet the newly issued Rating Certificate confirming Cerbios as a company with Risk Indicator of 1 (D&B Risk Indicators range from 1, minimum risk, to 4, high risk)
30.08.2011,
in
Soci 2011
